Developer docs
API playgroundTry for free, no card

Search company profiles

DiamiR

Full company profile

uuid0000n8t

Namestring
DiamiR
Legal namestring
DiamiR Biosciences Corp.
Websiteurl
diamirbio.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

DiamiR Biosciences Corp. is a molecular diagnostics company developing blood-based tests for the early detection and monitoring of neurodegenerative and neurodevelopmental disorders, built on a proprietary platform that analyzes brain-enriched microRNA (miRNA) biomarkers detectable in blood plasma. The company exploits the discovery that certain microRNAs are enriched in specific brain regions (hippocampus, midbrain), cells (neurons), and synaptic compartments, and can cross the blood-brain barrier to be measured peripherally. Its lead product candidate, CogniMIR, targets early detection of mild cognitive impairment and Alzheimer's disease, while a broader Universal Screening Test (UST) program uses organ-enriched miRNA panels for early pathology detection across organ systems. A March 2026 publication in the journal Diagnostics also demonstrated feasibility of a plasma-based miRNA test for glioblastoma, signaling expansion into CNS oncology.

The company operates a CLIA-certified, CAP-accredited clinical laboratory in New Haven, CT, and maintains clinical laboratory permits in New York, Connecticut, Maryland, California, and Pennsylvania. It sells miRNA testing services to pharmaceutical and biotechnology companies, academic medical centers, and CROs for biomarker discovery, patient identification and recruitment, treatment response monitoring, and clinical trial support, with results delivered in 3-5 business days. Co-founders Kira Sheinerman, PhD, MBA and Samuil Umansky, MD, PhD, Dr Sci anchor the science; Umansky holds over 80 US and international patents. The IP portfolio is broad: issued and pending patents cover brain-enriched miRNA technology alongside transrenal nucleic acid methods. Pricing is quote-based with no publicly disclosed tiers.

In July 2025, DiamiR entered into a definitive all-stock merger agreement with Aptorum Group Limited (NASDAQ: APM), under which DiamiR will become a wholly-owned subsidiary and the combined company will be headquartered in Princeton, NJ. Aptorum filed a registered direct offering of up to $6 million to finance the merger and general operations. Strategic partnerships include Instant NanoBiosensors (APOE platform validation, February 2026), New York Blood Center (Healthy Aging program, NIH/NIA-funded), and Tri-State Rett Syndrome Center at Montefiore (Rett syndrome biomarker development). Revenue figures are not disclosed; cumulative grant funding totals approximately $7.5 million across 2017-2020 from SBIR, NIH/NIA, NINDS, and the Alzheimer's Drug Discovery Foundation.

Short descriptiontext

DiamiR Biosciences is a molecular diagnostics company developing blood-based tests that detect brain-enriched microRNA biomarkers in plasma for early identification and monitoring of neurodegenerative disorders, serving pharmaceutical, biotech, and clinical research customers through its CLIA-certified laboratory.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, microRNA biomarkers, brain health diagnostics, clinical laboratory services, Alzheimer's detection
Industry4 codes
PRIMARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1miRNA Testing Services
TypeProfessional Services
Description

Laboratory testing services offered to pharmaceutical companies, researchers, and drug developers for biomarker discovery, patient identification, treatment monitoring, and clinical trial support. Services include sample collection, advanced miRNA expression analysis, and comprehensive reporting with 3-5 business day turnaround.

diamirbio.com
2Diagnostic Product Candidates
TypeOne Time License
Description

Development and potential commercialization of diagnostic products including CogniMIR for Alzheimer's disease detection and Universal Screening Test for organ health assessment.

diamirbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1CogniMIR™
Description

Lead product in development for early detection of mild cognitive impairment and Alzheimer's disease in the context of clinical studies.

diamirbio.com
Core offering1 text field

DiamiR provides blood-based molecular diagnostic testing services and develops diagnostic product candidates based on brain-enriched microRNA biomarkers detectable in plasma. From its CLIA-certified, CAP-accredited clinical laboratory in New Haven, CT, the company offers miRNA testing services with 3-5 business day turnaround for pharmaceutical and biotechnology companies, researchers, and clinical trial operators. Lead diagnostic product candidates include CogniMIR for early detection of mild cognitive impairment and Alzheimer's disease and the Universal Screening Test for organ-level pathology detection.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Neurodegeneration in Alzheimer's disease begins 15-20 years prior to clinical manifestation, enabling presymptomatic diagnosis potential
+1 more record
Product overview1 text field

DiamiR offers a portfolio of blood-based molecular diagnostics focused on brain health, built on its proprietary platform of brain-enriched microRNA biomarkers detectable in plasma. The core offerings include CogniMIR for early detection of mild cognitive impairment and Alzheimer's disease, microRNA Testing Services for research and clinical study support, and the Universal Screening Test (UST) for organ-level pathology detection. The company operates a CLIA-certified, CAP-accredited clinical laboratory in New Haven, CT, and also provides APOE testing platform validation services in partnership with Instant NanoBiosensors. All products leverage non-invasive blood sampling to capture signatures of brain and synaptic health.

Product and service3 records
1CogniMIR
CategoryDiagnostic product candidate
Description

Lead diagnostic product candidate using brain-enriched microRNA biomarkers in blood plasma for early detection of mild cognitive impairment and Alzheimer's disease, designed to support clinical study enrollment and disease monitoring for pharmaceutical and research customers.

2microRNA Testing Services
CategoryClinical laboratory testing services
Description

Laboratory testing services analyzing microRNA expression patterns from blood, plasma, saliva, or tissue samples, delivered from DiamiR's CLIA-certified, CAP-accredited laboratory in New Haven, CT, for pharmaceutical companies, biotech firms, and research institutions needing biomarker discovery, patient identification, treatment monitoring, and precision diagnostics support.

3Universal Screening Test (UST)
CategoryDiagnostic product candidate
Description

Blood-based universal screening test using organ-enriched microRNA panels to detect the presence of pathology in particular organ systems early, enabling follow-up with more specific diagnostic testing.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Instant NanoBiosensors
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-02
Description

Collaboration to validate Instant NanoBiosensors' automated apolipoprotein E (APOE) testing platform for clinical use in DiamiR's CLIA-certified, CAP-accredited clinical laboratory. The validation aims to expand DiamiR's service offerings and strengthen confidence in the INB platform for Alzheimer's disease diagnostics.

tipranks.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-07-16
Description

Definitive all-stock merger agreement where DiamiR will become a wholly-owned subsidiary of Aptorum Group. The merged company plans to operate under Nasdaq and will be headquartered in Princeton, New Jersey, with strategic focus on blood-based tests for brain health and other diseases.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on the Healthy Aging program, which is funded in part by a Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH). Program focuses on developing biomarkers of aging based on brain-enriched and inflammation-associated microRNAs in plasma.

4Tri-State Rett Syndrome Center at Montefiore Medical Center
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical study collaboration to investigate the potential of brain-enriched microRNA as biomarkers of Rett syndrome (RTT). Initial work conducted in animal models suggests the approach for developing minimally invasive biomarkers is feasible.

diamirbio.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborations with academia, medical centers, disease foundations and industry partners for development and commercialization of microRNA-based diagnostics for brain health and other diseases.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DiamiR

Molecular Diagnosticsdiamirbio.com

DiamiR Biosciences is a molecular diagnostics company developing blood-based tests that detect brain-enriched microRNA biomarkers in plasma for early identification and monitoring of neurodegenerative disorders, serving pharmaceutical, biotech, and clinical research customers through its CLIA-certified laboratory.

What DiamiR does

DiamiR Biosciences Corp. is a molecular diagnostics company developing blood-based tests for the early detection and monitoring of neurodegenerative and neurodevelopmental disorders, built on a proprietary platform that analyzes brain-enriched microRNA (miRNA) biomarkers detectable in blood plasma. The company exploits the discovery that certain microRNAs are enriched in specific brain regions (hippocampus, midbrain), cells (neurons), and synaptic compartments, and can cross the blood-brain barrier to be measured peripherally. Its lead product candidate, CogniMIR, targets early detection of mild cognitive impairment and Alzheimer's disease, while a broader Universal Screening Test (UST) program uses organ-enriched miRNA panels for early pathology detection across organ systems. A March 2026 publication in the journal Diagnostics also demonstrated feasibility of a plasma-based miRNA test for glioblastoma, signaling expansion into CNS oncology.

The company operates a CLIA-certified, CAP-accredited clinical laboratory in New Haven, CT, and maintains clinical laboratory permits in New York, Connecticut, Maryland, California, and Pennsylvania. It sells miRNA testing services to pharmaceutical and biotechnology companies, academic medical centers, and CROs for biomarker discovery, patient identification and recruitment, treatment response monitoring, and clinical trial support, with results delivered in 3-5 business days. Co-founders Kira Sheinerman, PhD, MBA and Samuil Umansky, MD, PhD, Dr Sci anchor the science; Umansky holds over 80 US and international patents. The IP portfolio is broad: issued and pending patents cover brain-enriched miRNA technology alongside transrenal nucleic acid methods. Pricing is quote-based with no publicly disclosed tiers.

In July 2025, DiamiR entered into a definitive all-stock merger agreement with Aptorum Group Limited (NASDAQ: APM), under which DiamiR will become a wholly-owned subsidiary and the combined company will be headquartered in Princeton, NJ. Aptorum filed a registered direct offering of up to $6 million to finance the merger and general operations. Strategic partnerships include Instant NanoBiosensors (APOE platform validation, February 2026), New York Blood Center (Healthy Aging program, NIH/NIA-funded), and Tri-State Rett Syndrome Center at Montefiore (Rett syndrome biomarker development). Revenue figures are not disclosed; cumulative grant funding totals approximately $7.5 million across 2017-2020 from SBIR, NIH/NIA, NINDS, and the Alzheimer's Drug Discovery Foundation.

DiamiR firmographics

Firmographics
Name
DiamiR
Legal name
DiamiR Biosciences Corp.
Website
https://diamirbio.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
1–10 employees
Short description
DiamiR Biosciences is a molecular diagnostics company developing blood-based tests that detect brain-enriched microRNA biomarkers in plasma for early identification and monitoring of neurodegenerative disorders, serving pharmaceutical, biotech, and clinical research customers through its CLIA-certified laboratory.
Ownership category
akta.pro rank

DiamiR industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Molecular diagnostics
  • MicroRNA biomarkers
  • Brain health diagnostics
  • Clinical laboratory services
  • Alzheimer's detection

Where DiamiR is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Offices2 records

Markets served

DiamiR business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. miRNA Testing Services: Laboratory testing services offered to pharmaceutical companies, researchers, and drug developers for biomarker discovery, patient identification, treatment monitoring, and clinical trial support. Services include sample collection, advanced miRNA expression analysis, and comprehensive reporting with 3-5 business day turnaround.
  2. Diagnostic Product Candidates: Development and potential commercialization of diagnostic products including CogniMIR for Alzheimer's disease detection and Universal Screening Test for organ health assessment.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

DiamiR product offering

Product offering

Core offering

DiamiR provides blood-based molecular diagnostic testing services and develops diagnostic product candidates based on brain-enriched microRNA biomarkers detectable in plasma. From its CLIA-certified, CAP-accredited clinical laboratory in New Haven, CT, the company offers miRNA testing services with 3-5 business day turnaround for pharmaceutical and biotechnology companies, researchers, and clinical trial operators. Lead diagnostic product candidates include CogniMIR for early detection of mild cognitive impairment and Alzheimer's disease and the Universal Screening Test for organ-level pathology detection.

Product overview

DiamiR offers a portfolio of blood-based molecular diagnostics focused on brain health, built on its proprietary platform of brain-enriched microRNA biomarkers detectable in plasma. The core offerings include CogniMIR for early detection of mild cognitive impairment and Alzheimer's disease, microRNA Testing Services for research and clinical study support, and the Universal Screening Test (UST) for organ-level pathology detection. The company operates a CLIA-certified, CAP-accredited clinical laboratory in New Haven, CT, and also provides APOE testing platform validation services in partnership with Instant NanoBiosensors. All products leverage non-invasive blood sampling to capture signatures of brain and synaptic health.

Differentiator

Problem solved

Functional benefit

Brands

  • CogniMIR™: Lead product in development for early detection of mild cognitive impairment and Alzheimer's disease in the context of clinical studies.

Products and services

  • CogniMIR Lead diagnostic product candidate using brain-enriched microRNA biomarkers in blood plasma for early detection of mild cognitive impairment and Alzheimer's disease, designed to support clinical study enrollment and disease monitoring for pharmaceutical and research customers.
  • microRNA Testing Services Laboratory testing services analyzing microRNA expression patterns from blood, plasma, saliva, or tissue samples, delivered from DiamiR's CLIA-certified, CAP-accredited laboratory in New Haven, CT, for pharmaceutical companies, biotech firms, and research institutions needing biomarker discovery, patient identification, treatment monitoring, and precision diagnostics support.
  • Universal Screening Test (UST) Blood-based universal screening test using organ-enriched microRNA panels to detect the presence of pathology in particular organ systems early, enabling follow-up with more specific diagnostic testing.

Quantifiable outcome

  • Neurodegeneration in Alzheimer's disease begins 15-20 years prior to clinical manifestation, enabling presymptomatic diagnosis potential
  • +1 more outcomes

Companies that use DiamiR

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

DiamiR technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

DiamiR partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, flagship and minor.

  • Instant NanoBiosensorscoreTechnology or Integration · 2 February 2026Collaboration to validate Instant NanoBiosensors' automated apolipoprotein E (APOE) testing platform for clinical use in DiamiR's CLIA-certified, CAP-accredited clinical laboratory. The validation aims to expand DiamiR's service offerings and strengthen confidence in the INB platform for Alzheimer's disease diagnostics.
  • Aptorum Group LimitedflagshipStrategic or Co-development Partner · 16 July 2025Definitive all-stock merger agreement where DiamiR will become a wholly-owned subsidiary of Aptorum Group. The merged company plans to operate under Nasdaq and will be headquartered in Princeton, New Jersey, with strategic focus on blood-based tests for brain health and other diseases.
  • New York Blood CentercoreStrategic or Co-development PartnerCollaboration on the Healthy Aging program, which is funded in part by a Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH). Program focuses on developing biomarkers of aging based on brain-enriched and inflammation-associated microRNAs in plasma.
  • Tri-State Rett Syndrome Center at Montefiore Medical CenterminorStrategic or Co-development PartnerClinical study collaboration to investigate the potential of brain-enriched microRNA as biomarkers of Rett syndrome (RTT). Initial work conducted in animal models suggests the approach for developing minimally invasive biomarkers is feasible.
  • Academia, Medical Centers, Disease Foundations, and Industry CollaboratorsminorStrategic or Co-development PartnerCollaborations with academia, medical centers, disease foundations and industry partners for development and commercialization of microRNA-based diagnostics for brain health and other diseases.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

DiamiR competitors and assessment

Company assessment

Market position

Strengths3 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

DiamiR social profiles

Digital presence

DiamiR compliance and trust

Trust signal

Compliance7 records

DiamiR financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DiamiR leadership team

Management profile

Number of profiles

Profiles6 records

DiamiR funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DiamiR M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DiamiR

What does DiamiR do?

DiamiR provides blood-based molecular diagnostic testing services and develops diagnostic product candidates based on brain-enriched microRNA biomarkers detectable in plasma. From its CLIA-certified, CAP-accredited clinical laboratory in New Haven, CT, the company offers miRNA testing services with 3-5 business day turnaround for pharmaceutical and biotechnology companies, researchers, and clinical trial operators. Lead diagnostic product candidates include CogniMIR for early detection of mild cognitive impairment and Alzheimer's disease and the Universal Screening Test for organ-level pathology detection.

Is DiamiR a public or private company?

DiamiR is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was DiamiR founded?

DiamiR was founded in 1998. It employs 1 to 10 people.

Where is DiamiR based?

DiamiR is headquartered in Princeton, United States, in the North America region.

How does DiamiR make money?

Two revenue lines are on record. miRNA Testing Services are the primary driver. The others are diagnostic Product Candidates.

Does DiamiR have an API?

No public API is recorded for DiamiR.

What industry is DiamiR in?

DiamiR's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR), with a secondary code of HLAFAMAE, Molecular Diagnostics & Genomics Laboratories. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanNiki BioSolutions signs Charter APOE testing agreementNiki BioSolutions' subsidiary DiamiR Biosciences signed an agreement to perform APOE genotyping for Charter Research, a multi-site clinical research network conducting Alzheimer's trials. The agreement brings CAP and NYS CLEP-approved genotyping to Charter's sites in Florida and Illinois. APOE status is increasingly used to inform eligibility and safety monitoring in Alzheimer's trials.Stock TitanNiki BioSolutions Selected for Rett Research Tool BeltNiki BioSolutions' subsidiary DiamiR Biosciences was selected for the International Rett Syndrome Foundation's "Rett Research Tool Belt" series. The company's blood-based microRNA panel targets 44 brain-enriched microRNAs, evaluated in over 200 individuals. The panel aims to monitor disease progression and treatment response in clinical trials.Stock TitanNiki BioSolutions Engages Fios for Alzheimer’s AnalysisNiki BioSolutions' subsidiary DiamiR Biosciences engaged Fios Genomics to provide bioinformatics and biostatistical analysis for its Alzheimer's disease testing program. The engagement will analyze complex datasets to inform target and biomarker decisions, supporting pipeline advancement. The work is expected to inform subsequent validation studies.Stock TitanNiki BioSolutions Signs Apolipoprotein E PartnershipNiki BioSolutions' wholly-owned subsidiary DiamiR Biosciences has entered into a partnership with Progressive Medical Research to provide Apolipoprotein E (APOE) genotyping services for the latter's clinical and translational research programs. The collaboration leverages Niki BioSolutions' CAP and CLEP-approved testing platform to generate validated genetic data for Alzheimer's disease, cardiovascular health, and lipid metabolism studies. Financial terms of the agreement were not disclosed.SahmcapitalAptorum Group Announces 1-For-10 Reverse Stock Split, Effective July 20; Proposed Merger With DiamiR Biosciences Anticipated To Close Around July 20Aptorum Group has announced a 1-for-10 reverse stock split effective July 20, 2026, approved by shareholders on June 9, 2026, to increase the per-share trading price for Nasdaq compliance. The company's proposed merger with DiamiR Biosciences is anticipated to close on or around July 20, 2026, following which Aptorum will redomicile as a Delaware corporation under the new name Niki BioSolutions, Inc. and trade under the symbol "NIKI" on the Nasdaq Capital Market on a split-adjusted basis.FinancialContent Business PageAptorum Group Provides Update on DiamiR Biosciences MergerAptorum Group announced the anticipated closing of its all-stock merger with DiamiR Biosciences Corp. on or about July 20, 2026, following shareholder approval on June 9, 2026. In connection with the merger, Aptorum will implement a 1-for-10 reverse stock split and redomicile from the Cayman Islands to Delaware, with the combined entity renamed Niki BioSolutions, Inc. trading on Nasdaq Capital Market under the ticker "NIKI." The reverse split is intended to increase the per-share trading price to maintain compliance with Nasdaq's minimum bid price requirement for continued listing.Stock TitanAptorum Merger Expected July 20; 1-for-10 SplitAptorum Group announced the anticipated closing of its all-stock merger with DiamiR Biosciences on or about July 20, 2026, following shareholder approval on June 9, 2026. The post-merger company will be renamed Niki BioSolutions, Inc. and trade on Nasdaq under the ticker "NIKI" with a new CUSIP number, after implementing a 1-for-10 reverse share split to meet Nasdaq's minimum bid price requirement for continued listing. As part of the transaction, Aptorum will redomicile from the Cayman Islands to Delaware, with DiamiR becoming a wholly-owned subsidiary of the combined entity.Longevity.TechnologyDiamiR to present three biomarker studies at 2026 AAICDiamiR Biosciences, a subsidiary of Aptorum Group Limited, will present three biomarker research posters at the Alzheimer's Association International Conference in London from July 11–15, 2026, covering plasma-based APOE genotyping and circulating microRNAs as blood biomarkers for mild cognitive impairment to Alzheimer's progression. The companies also noted that their previously announced all-stock merger, approved by shareholders on June 9, 2026, remains subject to customary closing conditions and is expected to close before fiscal 2027, after which DiamiR would become a wholly owned subsidiary and the combined entity would be renamed Niki BioSolutions, Inc.Stock TitanAptorum, DiamiR set 3 AAIC 2026 presentationsAptorum Group and DiamiR Biosciences announced they will present three scientific posters at the 2026 Alzheimer's Association International Conference in London from July 11-15, showcasing biomarker technologies including plasma-based APOE genotyping and circulating microRNA signatures for Alzheimer's disease progression. The presentations highlight DiamiR's CLIA-certified laboratory capabilities and follow the June 2026 shareholder approval of an all-stock merger between the two companies, which is expected to close before fiscal 2027. Upon completion, DiamiR will become a wholly-owned subsidiary of Aptorum and the combined entity will be renamed Niki BioSolutions.Longevity.TechnologyAptorum-backed DiamiR expands Alzheimer’s diagnostic effortsDiamiR Biosciences has announced a collaboration with AlzLabs Precision Diagnostics to evaluate blood-based biomarkers for Alzheimer's disease, including p-Tau 217, amyloid 42/40, and neurofilament light (NfL), using plasma samples with confirmed amyloid status. The study will also assess these markers alongside DiamiR's proprietary CogniMIR microRNA platform. The collaboration follows shareholder approval of the merger between Aptorum Group and DiamiR to form Niki BioSolutions, expected to close before fiscal 2027, potentially positioning the future company as a significant player in neurodiagnostics.